NASDAQ: ARVN

Arvinas Inc Stock Forecast, Predictions & Price Target

The consensus among 13 Wall Street analysts covering (NASDAQ: ARVN) stock is to Strong Buy ARVN stock.

Out of 13 analysts, 7 (53.85%) are recommending ARVN as a Strong Buy, 4 (30.77%) are recommending ARVN as a Buy, 2 (15.38%) are recommending ARVN as a Hold, 0 (0%) are recommending ARVN as a Sell, and 0 (0%) are recommending ARVN as a Strong Sell.

If you're new to stock investing, here's how to buy Arvinas stock.

(NASDAQ: ARVN) Arvinas's forecast annual revenue growth rate of 58.19% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.04%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.92%.

Arvinas's revenue in 2024 is $78,500,000.On average, 9 Wall Street analysts forecast ARVN's revenue for 2024 to be $11,809,157,312, with the lowest ARVN revenue forecast at $5,160,761,742, and the highest ARVN revenue forecast at $25,871,892,640. On average, 9 Wall Street analysts forecast ARVN's revenue for 2025 to be $16,692,204,712, with the lowest ARVN revenue forecast at $6,808,392,800, and the highest ARVN revenue forecast at $28,050,578,336.

In 2026, ARVN is forecast to generate $21,061,899,295 in revenue, with the lowest revenue forecast at $15,151,397,337 and the highest revenue forecast at $32,578,159,548.

According to 13 Wall Street analysts that have issued a 1 year ARVN price target, the average ARVN price target is $59.31, with the highest ARVN stock price forecast at $90.00 and the lowest ARVN stock price forecast at $20.00.

On average, Wall Street analysts predict that Arvinas's share price could reach $59.31 by Apr 15, 2025. The average Arvinas stock price prediction forecasts a potential upside of 87.68% from the current ARVN share price of $31.60.

(NASDAQ: ARVN) forecast ROE is N/A, which is considered weak.